Rucaparib camsylate
Rubraca (rucaparib camsylate) is a small molecule pharmaceutical. Rucaparib camsylate was first approved as Rubraca on 2016-12-19. It is used to treat ovarian neoplasms in the USA. It has been approved in Europe to treat ovarian neoplasms.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| rubraca | New Drug Application | 2024-02-21 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RUCAPARIB CAMSYLATE, RUBRACA, ZR PHARMA | |||
| 2025-04-06 | ODE-168 | ||
| 2023-12-19 | ODE-126 | ||
| 2023-05-15 | I-830 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Rucaparib Camsylate, Rubraca, Zr Pharma | |||
| 9987285 | 2035-08-17 | DP | |
| 10130636 | 2035-08-17 | U-2012, U-2101, U-2273, U-2830 | |
| 8859562 | 2031-08-04 | U-2012, U-2273, U-2830 | |
| 8754072 | 2031-02-10 | DS, DP | |
| 9045487 | 2031-02-10 | DS, DP | |
| 9861638 | 2031-02-10 | U-2012, U-2273 | |
| 10278974 | 2031-02-10 | DP | |
| 8071579 | 2027-08-12 | U-2012, U-2273, U-2830 | |
| 8143241 | 2027-08-12 | U-2012, U-2273, U-2830 | |
| 7351701 | 2024-07-23 | U-2012, U-2273, U-2830 | |
| 7531530 | 2024-07-23 | U-2012, U-2273, U-2830 | |
| 6495541 | 2023-11-22 | DS, DP | |
HCPCS
No data
Clinical
Clinical Trials
68 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malignant mesothelioma | D000086002 | — | — | — | 1 | — | — | — | 1 |
| Mesothelioma | D008654 | — | C45 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | — | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rucaparib camsylate |
| INN | — |
| Description | Rucaparib is a member of the class of azepinoindoles that is 1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one carrying additional 4-[(methylamino)methyl]phenyl and fluoro substituents at positions 2 and 8 respectively. It is an inhibitor of poly (ADP-ribose) polymerase and is used (as the camsylate salt) as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor and an antineoplastic agent. It is an azepinoindole, a member of caprolactams, an organofluorine compound and a secondary amino compound. It is a conjugate base of a rucaparib(1+). |
| Classification | Small molecule |
| Drug class | poly-ADP-ribose polymerase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC1(C)[C@@H]2CC[C@@]1(CS(=O)(=O)O)C(=O)C2.CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 283173-50-2 |
| RxCUI | 1862579 |
| ChEMBL ID | CHEMBL3833368 |
| ChEBI ID | — |
| PubChem CID | 9931954 |
| DrugBank | DB12332 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,524 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use